Noramco Announces Provisional Patent Application of Proprietary Cannabidiol (CBD)

Noramco, a global leading producer of controlled substances, including cannabinoids for the pharmaceutical industry, today announced that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) directed to its proprietary pure cannabidiol (CBD) compositions.

AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco

AXIM® Biotechnologies, Inc. announced that it has reached a long-term purchase agreement for pharmaceutical-grade dronabinol with Noramco, a global leader in the production of controlled substances for the pharmaceutical industry.

Noramco and SPI Pharma sign agreement to develop ready-to-implement, patient-friendly formulations for pharmaceutical manufacturers

Noramco and SPI Pharma have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceutical manufacturers…

Noramco adds 23 compounds to analytical reference standards catalogue

Noramco announced the addition of 23 new compounds to its analytical reference standards catalog – compounds pharmaceutical product developers require to validate product quality and to verify the integrity of production systems…

Noramco introduces controlled substance development solutions at CPhI Worldwide

Noramco is integrating its API development offering to include all of the technologies and services that generic and branded pharmaceutical producers require to advance solutions to market. The specialty API producer today introduced a comprehensive…

Noramco and SPI Pharma sign letter of intent to develop formulation solution packages

Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services…

Noramco introduces a turnkey approach to cannabinoid APIs at CPhI Worldwide

Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.